Results 211 to 220 of about 223,804 (293)

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Neuroplasticity and tinnitus: the role of Brain-Derived Neurotrophic Factor in pathogenesis and treatment. [PDF]

Front Neurosci
Miranda V, Castiglioni S, Maier JA.
europepmc   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Synergy between stem cell therapy and brain-derived neurotrophic factor (BDNF) in Parkinson's disease: a mini-review of combined neuroregenerative strategies. [PDF]

Chin Neurosurg J
Jonny J, Larasati AD, Sunjaya QA, Faried A.   +3 more
europepmc   +1 more source

Neurotrophic factors

Journal of Cellular Biochemistry, 1990
openaire   +2 more sources

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Müller glia-mediated protection of retinal ganglion cells from ethambutol-induced neurotoxicity through brain-derived neurotrophic factor. [PDF]

Cell Commun Signal
Cheng HC, Wong YH, Wang AG, Chen SW, Yang YL, Juan HC, Liou RH, Yu JY.   +7 more
europepmc   +1 more source

Anti‐inflammatory effects of physical stimuli: The central role of networks in shaping the future of pharmacological research

British Journal of Pharmacology, EarlyView.
Addressing complexity in the study of life sciences through Systems Biology and Systems Medicine has been transformative, making Systems Pharmacology the next logical step. In this review, we focus on physical stimuli, whose potential in pharmacology has been neglected, despite demonstrated therapeutic properties.
Veronica Paparozzi, Reyhaneh Hooshmandabbasi, Alessandro Ravoni, Ying Ma, Luigi Manni, Timothy J. Koh, Caroline Maake, Tiziana Guarnieri, Darong Lai, Vitalii Zablotskii, Christine Nardini   +10 more
wiley   +1 more source

Brain-Derived Neurotrophic Factor and Heat Shock Protein-32: Potential Targets for Microglial Response to Glucose and Oxygen Manipulation. [PDF]

Mol Neurobiol
Mussa BM, Srivastava A, Bajbouj K, Shafarin J, Rajan R, Hisham A.   +5 more
europepmc   +1 more source